Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director | May 08, 2026 | May 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 08, 2026 · Filed May 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,997 |
Ending reported balance
After 2026-05-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-08 · Grant · Acquired 3,251 · Balance 7,933 F1: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Row 2 · 2026-05-08 · Grant · Acquired 1,064 · Balance 8,997 F2: This restricted stock award was granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 75,372 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 75,372 |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
F2: This restricted stock award was granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Xylem Inc.
Report date May 16, 2024 · Filed May 17, 2024
Section 16 reporting ended · disclosed 2024-05-17. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 06, 2017 Filed Nov 8, 2017 20:15 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $32.38 | $0.00 |
DisclosureSEC source: 0001209191-17-059710 · doc4.xml · derivative · entry 4 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,247 Underlying: Common Stock · 50,000 shares Expires 2018-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 20:15 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 37,700 | $66.25 | $2,497,625.00 |
DisclosureSEC source: 0001209191-17-059710 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,131 F1 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $66.0 to $66.7 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 20:15 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionCommon Stock | 50,000 | $32.38 | $1,619,000.00 |
DisclosureSEC source: 0001209191-17-059710 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 20:50 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionStock option (right to buy) · Derivative | 9,933 | $0.00 Strike: $30.03 | $0.00 |
DisclosureSEC source: 0001209191-17-042554 · doc4.xml · derivative · entry 7 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,933 shares Expires 2018-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 20:50 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 9,933 | $55.05 | $546,801.72 |
DisclosureSEC source: 0001209191-17-042554 · doc4.xml · nonDerivative · entry 4 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,831 F1 · shares: The exercise and sale were made pursuant to a 10b5-1 plan adopted by the reporting person on June 1, 2016. F3 · price: This price represents the approximate weighted average price per Share of the Issuer that were executed at prices ranging from $55.00 to $55.30 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 20:50 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionCommon Stock | 9,933 | $30.03 | $298,283.02 |
DisclosureSEC source: 0001209191-17-042554 · doc4.xml · nonDerivative · entry 3 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise and sale were made pursuant to a 10b5-1 plan adopted by the reporting person on June 1, 2016. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 20:50 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionStock Option (right to buy) · Derivative | 56,199 | $0.00 Strike: $30.03 | $0.00 |
DisclosureSEC source: 0001209191-17-042554 · doc4.xml · derivative · entry 6 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,933 Underlying: Common Stock · 56,199 shares Expires 2018-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 20:50 UTC | Xylem Inc. XYL · Entity 430 | SaleCommon Stock | 56,199 | $55.00 | $3,091,057.40 |
DisclosureSEC source: 0001209191-17-042554 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,831 F1 · shares: The exercise and sale were made pursuant to a 10b5-1 plan adopted by the reporting person on June 1, 2016. F2 · price: This price represents the approximate weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"), of sales that were executed at prices ranging from $55.00 to $55.02 per Share. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 20:50 UTC | Xylem Inc. XYL · Entity 430 | Exercise / conversionCommon Stock | 56,199 | $30.03 | $1,687,627.87 |
DisclosureSEC source: 0001209191-17-042554 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercise and sale were made pursuant to a 10b5-1 plan adopted by the reporting person on June 1, 2016. Read SEC document |
| May 12, 2017 Filed May 15, 2017 21:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 588 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009787 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,563 F3 · shares: This restricted stock was granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 12, 2017 Filed May 15, 2017 21:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,034 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-009787 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,975 F1 · shares: These restricted stock units were granted on May 12, 2017 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board. F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Read SEC document |
| May 10, 2017 Filed May 11, 2017 23:50 UTC | Xylem Inc. XYL · Entity 430 | GrantCommon Stock | 2,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-031669 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,831 F1 · shares: Reflects the award of restricted stock units, which are scheduled to vest on the business day prior to the Xylem Inc. 2018 annual shareholder's meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.